Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS)

Xavier Poiré, Carlos Graux, Aurélie Ory, Julie Herman, Frédéric Baron, Hélène Schoemans, Philippe Lewalle, Ann De Becker, Dries Deeren, Zwi Berneman, Tessa Kerre, Pierre Zachée, Dominik Selleslag, Yves Beguin

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
Original languageEnglish
Pages (from-to)116-118
Number of pages3
JournalBone Marrow Transplantation
Volume57
Issue number1
DOIs
Publication statusPublished - Jan 2022

Bibliographical note

Funding Information:
FB has received travel grants and/or speaker honoraria from Celgene, AbbVie, Novartis, Pfizer and Sanofi. HS has received travel grants and/or speaker/advisor honoraria from Incyte, Janssen, Novartis, Jazz Pharmaceuticals, Takeda Celgene, AbbVie, MSD, and Therakos. YB has received travel grants and/or speaker/consulting honoraria from Celgene, AbbVie, Novartis, Pfizer, Janssens-Cilag, Amgen and Sanofi. The study was supported by a grant from Celgene Inc.

Copyright:
Copyright 2022 Elsevier B.V., All rights reserved.

Cite this